¹**Proteome-wide autoantibody screening and holistic autoantigenomic analysis** ²**unveil COVID-19 signature of autoantibody landscape**

- 17 2. Department of Computer Science, The University of Tokyo Graduate School of
- 18 Information Science and Technology, Tokyo, Japan

- 19 3. Department of Clinical Laboratory Medicine, The University of Tokyo Graduate
- 20 School of Medicine, Tokyo, Japan
- 21 4. Graduate School, International University of Health and Welfare, Tokyo, Japan
- 22 5. Department of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan
- 23 6. Division of Infection Prevention and Control, Postgraduate School of Healthcare,
- 24 Tokyo Healthcare University, Tokyo, Japan
- 25 7. Department of Clinical Cannabinoid Research, The University of Tokyo Graduate
- 26 School of Medicine, Tokyo, Japan
- 27 8. Department of Allergy and Rheumatology, The University of Tokyo Graduate
- 28 School of Medicine, Tokyo, Japan
- 29 9. ProteoBridge Corporation, Tokyo, Japan
- 30 10. NOV Academic Research, TOKIWA Pharmaceutical Co., Ltd., Tokyo, Japan
-
- 32 * Equally contributed.
- 33

³⁵**# Corresponding authors**

- 36 Ayumi Yoshizaki, MD, PhD
- 37 Department of Dermatology and Department of Clinical Cannabinoid Research, The
- ³⁸University of Tokyo Graduate School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo,
- 39 Japan, 1138655
- 40 Phone: +81-3-3815-5411
- ⁴¹ORCID: 0000-0002-8194-9140
- ⁴²E-mail: ayuyoshi@me.com
-

Abstract

- 62 responses in COVID-19 and other diseases. It provides a deeper understanding of the
- 63 autoimmunity landscape in human disorders and introduces a new bioresource for
- 64 further investigation.

65

⁶⁶**Introduction**

78 Humoral immunity plays pivotal roles in COVID-19. Although dramatic 79 success of mRNA vaccines and SARS-CoV-2 neutralizing monoclonal antibodies in 80 preventing serious illnesses, accumulating evidence have suggested the vicious roles of 81 dysregulated humoral immunity. As well as earlier work linking anti-cytokine 82 antibodies to mycobacterial, staphylococcal and fungal diseases,^{6,7} autoantibodies 83 against cytokines have been described in COVID-19.⁸ Especially, anti-type I Interferon

84	antibodies distinguished \sim 10% of life-threatening pneumonia and \sim 20% of deaths from
85	$COVID-19$. A high-throughput screening by yeast display of the secretome further
86	revealed the presence of autoantibodies against several immune factors, including
87	chemokines. ¹² In addition, autoantibodies characteristic of systemic autoimmune
88	disorders, such as anti-phospholipid antibodies, anti-nuclear antibodies and rheumatoid
89	factor, were reported in COVID-19. ¹³ More recently, association between COVID-19
90	severity and autoantibodies targeting G protein-coupled receptors and renin-angiotensin
91	system-related proteins has been reported. ¹⁴
92	To comprehensively understand such clinical significance of autoantibodies in
93	human diseases including COVID-19, high-precision autoantibody measurement with a
94	proteome-wide scale is necessary. Herein, we engaged our unique technology for
n r	$\mathbf{1}$ $\mathbf{$

95 proteome-wide autoantibody screening (PWAS) that covers approximately 90% of the 96 human transcriptome, $15-17$ in the serum samples derived from individual patients. Our 97 pipeline integrates human cDNA library $(HuPEX)$,¹⁸ a wheat germ cell-free system for 98 high-throughput *in vitro* protein synthesis,^{19–21} and technology for manipulating protein 99 arrays kept in moist conditions during the entire handling process, 22 namely wet protein 100 arrays (WPAs). We have applied this method in multiple inflammatory or malignant 101 disorders for validating its potential for illustrating the "autoantibody landscape" of

114

Results

Overview

Identification of disease-specific autoantibodies

We identified distinct sets of autoantibodies that showed a more than twofold 131 significant increase in each disease condition relative to HCs (Fig. 2B). Notably, certain 132 autoantibodies were unique to each disease (Fig. 2C). To illustrate the variability in

¹⁴⁴*Selection of machine learning frameworks*

145 To further investigate the association between autoantibody profiles and 146 COVID-19, we adopted a machine learning approach. We tested nine different methods 147 to differentiate COVID-19 cases from the others: simple linear regression, Ridge 148 regression, logistic regression with data normalization, logistic regression with data 149 standardization, support vector machine with data normalization, support vector 150 machine with data standardization, light gradient boosting machine (LightGBM), and

157 In our subsequent analysis using the entire dataset, we experimented with

158 binary (COVID-19 vs. others), ternary (mild COVID-19 vs. moderate to severe 159 COVID-19 vs. others), and multiclass (mild COVID-19 vs. moderate to severe 160 COVID-19 vs. AAV vs. AD vs. SSc vs. SLE vs. HCs) classifications through XGBoost. 161 The most significant autoantibodies identified across all models are depicted in **Fig. 3A**, ¹⁶²**3B, and 3C**, with autoantibodies against translational products from *BCL6 Corepressor* ¹⁶³*Pseudogene 1* (*BCORP1*) emerging as a top feature in every model. Similarly, 164 antibodies against K-Acetyltransferase 2A (KAT2A) were consistently prominent. 165 Notably, Anti-BCORP1 and anti-KAT2A Abs were highlighted as important items in 166 all the candidate machine learning methods tested (**Supplementary Fig. 3**). There was a 167 correlation between anti-BCORP Abs and anti-KAT2A Abs as illustrated in Fig. 3D, ¹⁶⁸**3E, and 3F**. Remarkably, established serum markers for SSc and SLE, such as

¹⁷⁹*Clinical relevance of autoantibodies*

180 The serum levels of the top 20 autoantibodies highlighted through multi-class 181 classification for each participant were depicted in a heatmap (Fig. 4A). Hierarchical 182 clustering identified three unique groups of autoantibodies: cluster I, which included 183 two autoantibodies highly specific to COVID-19 (anti-BCORP1 and anti-KAT2A Abs); 184 cluster II, comprising autoantibodies that are commonly elevated across various 185 conditions; and cluster III, involving well-established biomarkers for SSc and SLE. 186 Principal component analysis (PCA) effectively distinguished between seven categories

Time course of autoantibody levels during COVID-19

Discussion

256 target of the detected anti-BCORP1 Abs in our study. However, this theory remains 257 unconfirmed as our cDNA library did not include *BCOR* cDNA to validate this 258 hypothesis.

²⁵⁹Anti-KAT2A antibodies were also found to be specifically elevated in the sera 260 of COVID-19 patients (Fig. 4F). Like anti-BCORP1 Abs, the levels of anti-KAT2A 261 Abs increased over the course of COVID-19 but were not correlated to antibodies 262 targeting SARS-CoV-2 particles (Fig. 5H). This observation indicates that 263 autoantibodies to KAT2A emerge because of autoantigen exposure due to tissue 264 damage triggered by COVID-19, not as a reflection of cross-reaction between 265 SARS-CoV-2 virions. KAT2A functions as a histone acetyltransferase that plays a role 266 in the epigenetic regulation of the genome by modifying chromatin structures. There is 267 notable research by John K. et al., indicating that the SARS-CoV-2 ORF8 protein 268 mimics the histone H3's ARKS motifs, which interfere with the role of KAT2A role in 269 host cell epigenetic regulation.²⁶ Intriguingly, patients who did not show an increase in 270 anti-KAT2A antibodies were more often those requiring intensive care and mechanical 271 ventilation (**Supplementary Table 5**). This observation has led to the proposition that 272 the presence of anti-KAT2A Abs could be indicative of an effective immune response 273 to the virus by KAT2A upregulation, a hypothesis that warrants further research.

²⁷⁴Our study has multiple strengths. First, the wheat-germ *in vitro* protein 275 synthesis system and technique for manipulation of WPAs realized high-throughput 276 expression of various human proteins including exoproteome upon a single platform. ²⁷⁷Second, as a result, our autoantibody measurement could cover a wider range of 278 antigens at an almost proteome-wide level, which enabled us to apply omics-based 279 bioinformatical approaches for interpreting the data. Third, we investigated the 280 longitudinal change of autoantibody profiles within COVID-19 patients, along with the 281 measurement of antibodies targeting SARS-CoV-2 particles. The limitation of our 282 present study includes its retrospective design and a relatively small number of the 283 subjects. Furthermore, we could not distinguish whether the autoantibodies found in our 284 measurement were predisposed before COVID-19 or newly appeared after infection. In ²⁸⁵addition, functional assays for the autoantibodies such as neutralizing assays or *in vivo* 286 studies are lacking. Therefore, insights into the direct contribution of each autoantibody 287 to the pathophysiology of COVID-19 are limited. Our next challenges would include 288 collecting serum samples before and after COVID-19 by accessing to population-based 289 cohorts, evaluating the function of each autoantibody against their target molecules, and 290 testing their contribution to the pathogenesis in animal experiments.

²⁹²**References**

309 doi:10.1038/s41577-023-00933-2.

9, 1–21 (2022).

- 361 anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan.
- ³⁶²*Sci. Rep.* **¹¹**, 1–10 (2021).
- ³⁶³29. Qian, C. *et al.* Development and multicenter performance evaluation of fully
- ³⁶⁴automated SARS-CoV-2 IgM and IgG immunoassays. *Clin. Chem. Lab. Med.* **⁵⁸**,
- ³⁶⁵1601–1607 (2020).
- 366 30. Zhou, Y. *et al.* Metascape provides a biologist-oriented resource for the analysis
- ³⁶⁷of systems-level datasets. *Nat. Commun.* **¹⁰**, 1523 (2019).
-
- 369

Materials and Methods

Human subjects

Measurement of IgG targeting SARS-CoV-2 particles

415

$$
Autoantibody level [AU] = \frac{F_{autoantigen} - F_{negative \ control}}{F_{positive \ control} - F_{negative \ control}} \times 100
$$

416 AU arbitrary unit

417 $F_{autoantigen}$: fluorescent intensity of autoantigen spot

418 $F_{\text{negative control}}$ fluorescent intensity of negative control spot

419 $F_{positive\,control}$ fluorescent intensity of positive control spot

420

⁴²¹*Machine learning*

Statistical analysis

436 Differentially elevated autoantibodies were defined as more than 2-fold 437 changes in the serum levels with a P value < 0.01 . Gene Ontology Analysis using 438 web-based tools targeted the list of the entry clones coding the differentially highlighted 439 autoantigens was performed for gene-list enrichment analysis, gene-disease association

440 analysis, and transcriptional regulatory network analysis with Metascape.³⁰ Other data

441 analyses and presentations were conducted using Stata IC/15.0 (StataCorp, TX, USA).

⁴⁴³*Data visualization*

444 Box plots, scatter plots, hierarchical clustering and correlation matrix were 445 visualized by using R $(v4.2.1)$. Box plots were defined as follows: the middle line 446 corresponds to the median; the lower and upper hinges correspond to the first and third 447 quartiles; the upper whisker extends from the hinge to the largest value no further than 448 1.5 times the interquartile range (IQR) from the hinge; and the lower whisker extends 449 from the hinge to the smallest value at most 1.5 times the IQR of the hinge.

⁴⁵¹**Acknowledgements**

Author Contributions

Conflict-of-interest statement

Figure legends

Figure 1. Scheme of PWAS pipeline.

In the first step, proteins were synthesized *in vitro* from the proteome-wide human cDNA library (HuPEX). Promotors (P), Enhancers (E), and FLAG-GST tags were fused to open reading frames of the expression clones by Gateway LR reaction. After polymerase chain reaction amplification and *in vitro* transcription, translation was performed using the wheat germ cell-free synthesis system. In the second step, we prepared WPAs by plotting synthesized proteins onto glass slides in an array format. WPAs were treated with serum samples derived from diseased patients or HCs. Autoantibodies were detected by fluorochrome-conjugated anti-human IgG Ab. In the third step, autoantibody quantification was performed based on the fluorescent values. Analysis of acquired high-dimensional autoantibody profiles was conducted by multiple omics-based approaches. ORF: open reading frame.

Figure 2. Identification of disease-specific autoantibodies.

(A) Box plots that show SAL in each condition. NS: $P > 0.01$, *: $P < 0.01$, ***: $P <$ 0.0001. **(B)** Volcano plots that illustrate differentially elevated autoantibodies within each condition. Red horizontal dash lines indicate P values = 0.01. Red vertical dash lines indicate $Log2$ Fold Change (Disease/HC) = ± 1 . **(C)** Venn diagram that demonstrates the subsumptions among disease-specific autoantibodies. **(D)** UMAP plot that illustrates the distribution of disease-specific autoantibody profiles of each individual. **(E)** Heat map that shows the result of enrichment analysis targeting the genes responsible for the proteins targeted by such disease-specific autoantibodies. **(F)** Circos plot that depicts the overlap of the gene lists responsible for the proteins targeted by the disease-specific autoantibodies at the biological function level.

Figure 3. Autoantibodies highlighted in each machine learning model. Autoantibodies that are mostly highlighted according to feature importance in two-class **(A)**, three-class **(B)**, and multi-class **(C)** classifications. Correlograms depict correlations, showcasing the connection between the highest-ranked autoantibodies in two-class **(D)**, three-class **(E)**, and multi-class **(F)** classifications. The correlation strength is denoted by Spearman's rho on the color scale. Circle sizes represent the significance of the p-values, with only those with $P < 0.01$ being displayed. Radar charts present the average normalized quantities of the most important autoantibodies in each model, with line colors distinguishing between different disease categories in two-class **(G)**, three-class **(H)**, and multi-class **(I)** classifications.

Figure 4. COVID-19 signature of autoantibody landscape. (A) The heatmap's columns display the serum autoantibody concentrations highlighted in the multi-class classification using XGBoost. **(B)** PCA graph plots individual participants as points, with color coding to differentiate among various disease classes. **(C)** The loading diagram illustrates the contributions to PC1 and PC2, with I, II, and III marking the clusters defined in (A). **(D)** The bar graphs show the loadings of each autoantibody on PC1 and PC2. **(E)** A box plot presents the serum levels of anti-BCORP1 Abs in the subjects. **(F)** Another box plot indicates the serum levels of anti-KAT2A Abs in the subjects. Red vertical dash lines indicate mean + 2SD in HC.

Figure 5. Longitudinal change of humoral immune response in COVID-19. (A)

This box plot outlines the serum concentrations of IgG antibodies against N, S, or RBD in patients with COVID-19 at two intervals: "early" signifies within 10 days of symptom onset, and "late" refers to 11-20 days after symptoms appear. A red dashed line marks the threshold for a positive test result. ***: P < 0.0001. **(B)** These box plots demonstrate the SAL in patients with COVID-19 during the "early" and "late" time points. NS: $P > 0.01$. (C) The volcano plot highlights biomarkers that are significantly increased (in red) or decreased (in blue) over time in patients with COVID-19. **(D)** A Venn diagram illustrates the overlap between autoantibodies that changed over time and those specific to COVID-19. **(E)** The correlogram visualizes the relationships between the overlapping autoantibodies that either increased over time or are specific to COVID-19, with the color scale indicating the strength of correlation according to Spearman's rho and circle sizes depicting the significance of p-values, focusing on those with $P < 0.01$. (F) These box plots depict the time-based evolution of serum levels of anti-BCORP1 and anti-KAT2A antibodies in COVID-19 patients, categorized by disease severity. **(G)(H)** The scatter plots illustrate the correlation between serum levels of anti-BCORP or anti-KAT2A Abs and IgG antibodies against the COVID-19 components at different time points, as well as their progression over time. The red lines

and the surrounding shaded areas indicate the regression line and the 95% confidence

interval, respectively.

Supplementary Figure 1. The sum of autoantibody levels by sex and age. (A) The

sum of autoantibody levels (SAL) in males. **(B)** SAL in females. **(C)** SAL for age < 50

years old. **(D)** SAL for age >= 50 years old.

Supplementary Figure 2. Autoantibodies to cytokines or their receptors. (A) The heatmap's columns display the serum autoantibody concentrations targeting cytokines in each subject evaluated by our proteome-wide autoantibody screening. **(B)** The heatmap's columns display the serum autoantibody concentrations targeting cytokine receptors in each subject evaluated by our proteome-wide autoantibody screening. **(C)** A box plot presents the serum levels of anti-interferon alpha 2 (IFNA2) Abs in the subjects. **(D)** Another box plot indicates the serum levels of anti-interferon alpha 4 (IFN4A) Abs in the subjects.

Supplementary Figure 3. Feature importance of top highlighted autoantibodies in other candidate machine learning frameworks. (A) Simple linear regression. **(B)** Ridge regression. **(C)** Logistic regression with normalization. **(D)** Logistic regression with standardization. **(E)** SVM with normalization. **(F)** SVM with standardization. **(G)** LightBGM. **(H)** Random Forest.

Supplementary Figure 4. Serum levels of anti-BCORP1 and anti-KAT2A Abs by

sex and age. (A) Serum levels of anti-BCORP1 Abs by sex. F: female, M: male. **(B)**

Serum levels of anti-BCORP1 Abs by age. **(C)** Serum levels of anti-KAT2A Abs by sex.

(D) Serum levels of anti-KAT2A Abs by age. Red vertical dash lines indicate mean +

2SD in HC.

COVID-19

UMAP Plot

